The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation.
April’s PME also sees Professor Brian D Smith take a look at the ‘disease organisation’, arguing that, like humans, organisations too can be afflicted by genetic disorders that hinder performance and threaten survival (but he says they can be understood and cured).
And Mundipharma International’s head of market access Will Dunlop talks to us about a new framework to guide development programmes to a better destination. “It is about keeping drug development on track and if we do that the industry can save money and work more efficiently, and payers will get the drugs they want at the value they want while patients get the drugs they need,” he says, adding: “Sometimes science isn’t enough.”
But back to Brexit, and all the signs are that process will be just as combative as the above image suggests, on top of which it’s certain to be a marathon not a sprint.
But we can hope the European Council will be able “minimise the uncertainty caused by the decision of the UK for our citizens, businesses and member states”, as prioritised in its draft statement on Brexit.
• Read April’s issue of PME (Pharmaceutical Market Europe)